A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma

Stopped early · Phase 1

Conditions studied: Refractory Multiple Myeloma

In brief

This is a phase 1 study to evaluate the safety and determine maximum tolerated dose, safety \& tolerability of noscapine HCl in patients with advanced multiple myeloma

Key facts

Study ID

NCT00912899

Run by

Cougar Biotechnology, Inc.

People needed

12

Starts

2007-12-01

Expected to finish

2010-07-01

Last updated by the study team

2016-10-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced Multiple Myeloma.
• Progression after ≥ 2 lines of prior therapy, including at least one steroid, one immunomodulatory agent (iMID), one alkylator, and bortezomib (VELCADE®).
• ECOG performance status of either 0 or 1.

You may not qualify if…

• Prior chemotherapy with antimicrotubule agents
• Metastasis involving the brain or spinal cord
• Clinically significant lung or heart disease
• Abnormal electrocardiogram
• Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.
• Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.

Where it is running

• UCLA — Los Angeles, California, United States
• St. Vincent's Comprehensive Cancer Center — New York, New York, United States
• Weill Medical College of Cornell University — New York, New York, United States
• Columbia Presbyterian Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.